SR One shows no nerves in funding NeuroTherapeutics

Drug company GlaxoSmithKline’s in-house venture capital division has co-led the $43m second round of funding for US-based NeuroTherapeutics Pharma.

The series B round for the Chicago-based developer of therapies for central nervous system disorders, was also co-led by two other new investors, Fidelity Biosciences and MPM Capital, as well as SR One’s corporate venturing peer, Pfizer Venture Investments.

NeuroTherapeutics’ original backers were Novo Ventures, the corporate venture unit of Denmark-based foundation Novo, which invested between DKr10m ($1.7m) and DKr25m…